Drug Profile
MEDI 0639
Alternative Names: Anti-DLL-4 MAb; MEDI0639Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action DLL4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Small cell lung cancer
- Discontinued Solid tumours
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Small-cell-lung-cancer in USA (IV)
- 12 Sep 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
- 08 Oct 2015 Phase-I development for Solid tumours (Late-stage disease) is ongoing in USA (NCT01577745)